Connie Hirsh, MD
Psychiatry · Columbus, OHNPI 1245374891
Payments from drug & device makers
Across 118 payments — averaging $13.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$417
- AbbVie$321
- Sunovion Pharmaceuticals Inc.$266
- Neurocrine Biosciences, Inc.$129
- Takeda Pharmaceuticals U.S.A., Inc.$76
- Avanir Pharmaceuticals, Inc.$73
- plus $329 from 13 others
What the payments were for
- Food & beverage$1,606100%
- Gifts$30%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 21 | $417 |
| AbbVie(2 entities) | 34 | $321 |
| Sunovion Pharmaceuticals Inc. | 17 | $266 |
| Neurocrine Biosciences, Inc. | 7 | $129 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $76 |
| Avanir Pharmaceuticals, Inc. | 5 | $73 |
| Eisai Inc. | 3 | $54 |
| Bausch Health US, LLC | 4 | $54 |
| Lundbeck LLC | 3 | $45 |
| Shire North American Group Inc | 3 | $37 |
| Jazz Pharmaceuticals Inc. | 2 | $28 |
| Vanda Pharmaceuticals Inc. | 1 | $23 |
| Adlon Therapeutics L.p. | 1 | $17 |
| Neos Therapeutics, LP | 1 | $16 |
| Alfasigma USA, Inc. | 1 | $14 |
| Johnson & Johnson | 1 | $13 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $12 |
| Ironshore Pharmaceuticals Inc. | 1 | $12 |
| Validus Pharmaceuticals LLC | 3 | $3 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- REXULTI$117
How this compares
$1,609 in reported general payments places this provider in the 75th percentile of 1,119 psychiatry providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Aripiprazole | 17 | $1,169 |
| Carbamazepine ErCarbamazepine | 13 | $635 |
| Ziprasidone Hcl | 11 | $633 |
| Quetiapine Fumarate | 36 | $590 |
| Buspirone Hcl | 23 | $434 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 13 | $431 |
| Lamotrigine | 39 | $295 |
| Bupropion XlBupropion Hcl | 15 | $292 |
| Duloxetine Hcl | 15 | $232 |
| Sertraline Hcl | 34 | $216 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 15 | $156 |
| Trazodone Hcl | 12 | $111 |
| Fluoxetine Hcl | 13 | $48 |
| Lorazepam | 20 | $40 |
| Alprazolam | 14 | $13 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Columbus
- Fred RomeoColumbus$2.3M
- Michael SaribalasColumbus$1.2M
- Kevin WareColumbus$1.1M
- Kevin ReevesColumbus$286K
- Dallas ErdmannColumbus$125K
- Daniel LeeColumbus$113K
- Peter ZafiridesColumbus$109K
- Shishuka MalhotraCanton$15M
- Henry NasrallahCincinnati$3.8M
- Otto DuenoDayton$3.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.